Our research points to an autoimmune response to ACE-2 as the primary trigger for immune dysregulation in COVID-19. In the vaccinated, the vaccine spike protein can bind to serum ACE-2; this may lead a persistent low-level autoimmune response.
Due to priming of the immune system through vaccination, an autoimmune response could be triggered earlier than normal on re-exposure to the viral spike protein through COVID-19 infection or further vaccination.
Within a few days of experiencing symptoms (instead of the normal 8 days after symptoms first start), those patients who are vulnerable to severe disease could deteriorate, with breathing difficulties associated with the targeting of blood vessels in the lungs by autoantibodies to ACE-2.
The main cause of breathing difficulties is likely to be inflammation of the lung capillaries due to the autoantibodies to ACE-2, and the resulting microthrombi. Early intervention with high-dose steroids would be essential to reduce the risk of severe breathing difficulties and longer-term lung damage from inflammation.
Repeated exposure to the viral spike protein could cause early progressive autoimmune lung fibrosis with intractable shortness of breath.
Create your profile
Only paid subscribers can comment on this post
Check your email
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.